Clinical Effect of Rebamipide on Chronic Gastritis
Overview
To investigate the clinical effect of rebamipide in chronic gastritis patients. Patients with chronic gastritis were randomly divided into the experimental group and the control group. The experimental group were treated with rebamipide 0.1g tid and optimization of life style, and the control group were only optimized their life style for 26 weeks. Upper gastrointestinal endoscopy was performed in all patients to evaluate the severity of gastritis by modified Lanza score (MLS) and the histology by the updated Sydney system before and after treatment.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: June 2014
Interventions
- Drug: Rebamipide
- Rebamipide is a
- Behavioral: optimization of life style
Arms, Groups and Cohorts
- Experimental: experimental
- The experimental group were treated with rebamipide 0.1g tid and optimization of life style.
- Placebo Comparator: control
- The control group were only optimized their life style.
Clinical Trial Outcome Measures
Primary Measures
- modified Lanza score
- Time Frame: 26 weeks
- visual Analog scale
- Time Frame: 26 weeks
- to describe the inflamamtory of gastric mucosa pathologically
Participating in This Clinical Trial
Inclusion Criteria
- With the symptoms as follow: epigastric pain, abdominal discomfort, abdominal distention, poor appetite, nausea, vomiting and so on – diagnosed as chronic gastritis with endoscopic and pathological methods – agree to join in this clinical trail Exclusion Criteria:
-
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- BangMao Wang
- Provider of Information About this Clinical Study
- Sponsor-Investigator: BangMao Wang, Chief of Gastroenterology Department – Tianjin Medical University General Hospital
- Overall Official(s)
- Wang Bang-mao, Study Chair, Tianjin meidcal university general hospital,China
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.